2013
Investigation of the Interactions between Methadone and Elvitegravir-Cobicistat in Subjects Receiving Chronic Methadone Maintenance
Bruce RD, Winkle P, Custodio JM, Wei X, Rhee MS, Kearney BP, Ramanathan S, Friedland GH. Investigation of the Interactions between Methadone and Elvitegravir-Cobicistat in Subjects Receiving Chronic Methadone Maintenance. Antimicrobial Agents And Chemotherapy 2013, 57: 6154-6157. PMID: 24080665, PMCID: PMC3837895, DOI: 10.1128/aac.01229-13.Peer-Reviewed Original ResearchConceptsEVG/COBIBaseline valuesEffect of elvitegravirOpioid-dependence therapiesHIV-seronegative subjectsConcentration-time curveChronic methadone maintenanceDependence therapyOpioid withdrawalMethadone pharmacokineticsDosing periodMethadone maintenanceHistorical controlsPharmacodynamic studiesPharmacokinetic parametersMethadoneCobicistatElvitegravirMean areaAUCtauPharmacodynamicsCmaxSubjectsCOBISteady-state evaluationThe Pharmacokinetic and Pharmacodynamic Interactions Between Buprenorphine/Naloxone and Elvitegravir/Cobicistat in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment
Bruce RD, Winkle P, Custodio JM, Wei LX, Rhee MS, Kearney BP, Ramanathan S, Friedland GH. The Pharmacokinetic and Pharmacodynamic Interactions Between Buprenorphine/Naloxone and Elvitegravir/Cobicistat in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2013, 63: 480-484. PMID: 23599011, DOI: 10.1097/qai.0b013e3182961d31.Peer-Reviewed Original ResearchConceptsEVG/COBIBuprenorphine/naloxoneBaseline valuesBuprenorphine/naloxone treatmentEffect of elvitegravirElvitegravir/cobicistatOpioid-dependence therapiesHIV-seronegative subjectsNorbuprenorphine levelsOpioid pharmacodynamicsOpioid withdrawalNaloxone treatmentPharmacodynamic interactionsBuprenorphine/Historical controlsPharmacodynamic studiesAUCtauCobicistatNaloxoneCmaxElvitegravirTherapySubjectsCOBISteady-state evaluation
2006
Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine
McCance-Katz EF, Moody DE, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Smith P, Ogundele A, Jatlow P, Rainey PM. Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine. Clinical Infectious Diseases 2006, 43: s224-s234. PMID: 17109309, DOI: 10.1086/508187.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlkynesArea Under CurveBenzoxazinesBuprenorphineCase-Control StudiesCohort StudiesCyclopropanesDelavirdineDose-Response Relationship, DrugDrug Administration ScheduleDrug InteractionsFemaleHIV InfectionsHumansMaleNarcotic AntagonistsOpioid-Related DisordersOxazinesProbabilityPrognosisReference ValuesReverse Transcriptase InhibitorsRisk AssessmentStatistics, NonparametricTreatment OutcomeConceptsNonnucleoside reverse transcriptase inhibitor efavirenzReverse transcriptase inhibitor efavirenzInhibitor efavirenzPharmacokinetics of buprenorphineOpiate withdrawal symptomsAdjustment of dosesEffects of buprenorphineHuman immunodeficiency virusConcentration-time curveOpioid-dependent participantsHealthy control participantsAntiretroviral administrationAdverse eventsAgonist medicationsHIV diseaseNegative volunteersStandard dosesOpioid dependenceImmunodeficiency virusBuprenorphine concentrationsWithdrawal symptomsAntiretroviral pharmacokineticsDrug interactionsOpiate dependenceBuprenorphine
1999
Methadone and antiretroviral medications, part II.
Gourevitch M, Friedland G. Methadone and antiretroviral medications, part II. Infectious Diseases 1999, 11: 37, 43, 45-6. PMID: 11367102.Peer-Reviewed Original ResearchMethadone and antiretroviral medications, part I.
Gourevitch M, Friedland G. Methadone and antiretroviral medications, part I. Infectious Diseases 1999, 11: 30-1 contd. PMID: 11366210.Peer-Reviewed Original Research
1998
Methadone Effects on Zidovudine Disposition (AIDS Clinical Trials Group 262)
McCanceKatz E, Rainey P, Jatlow P, Friedland G. Methadone Effects on Zidovudine Disposition (AIDS Clinical Trials Group 262). JAIDS Journal Of Acquired Immune Deficiency Syndromes 1998, 18: 435-443. PMID: 9715839, DOI: 10.1097/00042560-199808150-00004.Peer-Reviewed Original ResearchConceptsInjection drug usersMethadone treatmentChronic methadone treatmentMethadone-maintained patientsHeroin-addicted patientsMethadone effectsZDV doseZDV exposureZDV pharmacokineticsZDV treatmentZidovudine dispositionZidovudine therapyHIV diseaseMethadone levelsPharmacokinetic interactionsTherapeutic rangeRenal clearanceToxicity surveillanceSide effectsDrug usersDrug efficacyZDVClearanceAUCPatients